INCY catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 1NCT06551584Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCTStanford University · Acute Myeloid LeukemiaRecruitingINCYCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT05298293Electronic MonitorIng of Events for dIffuse Large b Cell LYmphomaWeprom · Diffuse Large B Cell LymphomaNot yet recruitingINCYCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 1, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT05491226Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and RadiationStephen Shiao · TNBC - Triple-Negative Breast CancerRecruitingMRKCollaboratorINCYCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 1, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07049575Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis SuppurativaIncyte Corporation · Hidradenitis SuppurativaRecruitingINCYLead
- Enrollment
- Locked
- Primary completion
- Dec 9, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06212999A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis SuppurativaIncyte Corporation · Hidradenitis Suppurativa (HS)Active, not recruitingINCYLead
- Enrollment
- Locked
- Primary completion
- Dec 26, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedEarly Phase 1NCT04161248Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell LymphomaCanadian Cancer Trials Group · Lymphoma, B-CellActive, not recruitingINCYCollaboratorABBVCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT04659616Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid LeukemiaOHSU Knight Cancer Institute · Acute Myeloid LeukemiaRecruitingINCYCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT04661007To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins...Incyte Biosciences Japan GK · Non Hodgkins LymphomaActive, not recruitingINCYLead
- Enrollment
- Locked
- Primary completion
- Jul 1, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT03414229A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced SarcomaMemorial Sloan Kettering Cancer Center · SarcomaActive, not recruitingMRKCollaboratorINCYCollaborator
- Enrollment
- Locked
- Primary completion
- Sep 9, 2024Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT05714072A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of MyelofibrosisMemorial Sloan Kettering Cancer Center · Myelofibrosis Due to and Following Polycythemia VeraRecruitingLLYCollaboratorINCYCollaborator
- Enrollment
- Locked
- Primary completion
- Jan 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT06179160A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D MutationIncyte Corporation · Solid TumorsRecruitingINCYLead
- Enrollment
- Locked
- Primary completion
- Jan 1, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07559396A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal...Incyte Corporation · Renal ImpairmentRecruitingINCYLead
- Enrollment
- Locked
- Primary completion
- Jan 4, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06649201Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome EvaluationCase Comprehensive Cancer Center · Graft Vs Host DiseaseRecruitingINCYCollaborator
- Enrollment
- Locked
- Primary completion
- Nov 2026Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 13 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.